Press Releases
March 05, 2010
 | Resverlogix Market Update |
March 05, 2010
| Resverlogix Update |
February 27, 2010
| ASSURE 1 Initiation |
February 08, 2010
| Recruitment Completed for ASSERT |
February 01, 2010
| Bayer HealthCare CEO to Join RVX |
January 28, 2010
| RVX Closes Additional $8 Million |
January 11, 2010
| JP Morgan Healthcare Conference & Biotech Showcase |
January 07, 2010
| Repurchase of Debenture Debt |
December 23, 2009
| RVX Announces Financing |
December 22, 2009
| Phase 2 Dosing Starts 2 Months Early |
December 16, 2009
| RVX Enters $25 Million Agreement |
November 18, 2009
| RVX to Repurchase Convertible Debt |
October 26, 2009
| Dr. Cochrane's Induction to the Medical Hall of Fame |
October 16, 2009
| Clinical Trial Planning Update |
October 13, 2009
| RVX appoints new CFO |
September 29, 2009
| Top Line Clinical Trial Results |
September 25, 2009
| Teleconference to Discuss Clinincal Trial Results |
August 25, 2009
| Clinical Endpoint Met |
May 19, 2009
| Success in Inflammation Results in Patent Filings |
April 28, 2009
| Quarterly Update |
April 15, 2009
| Closing of Financing |
April 06, 2009
| US $20M Financing |
March 11, 2009
| RVX Announcing Financing |
November 26, 2008
| Active Negotiations Still Allow for Blackout Lift |
November 10, 2008
| Early Potential for Alzheimer's Disease |
November 10, 2008
| RVX Presents Data at AHA |
October 21, 2008
| RVX Advances to Second Arm of 1b/2a Trial |
October 15, 2008
| RVX Eliminates 60% of Debt |
October 07, 2008
| International IVUS Steering Committee |
October 07, 2008
| Management Issues Statement |
September 03, 2008
| Board of Directors Update |
September 02, 2008
| RVX Presented Scientific Data in Munich |
August 25, 2008
| Phase 1b/2a Program Begins |
August 21, 2008
| Conference Call August 25th 11 am MDT |
July 25, 2008
| Jan Gray, CA Appointed to Board |
July 18, 2008
| RVX Highlighted in Well Regarded Journal |
July 09, 2008
| RVX-208 Among Top 10 Most Promising CVD Drugs |
June 19, 2008
| Collaboration with Cleveland Clinic |
June 18, 2008
| Exploratory Efficacy Analysis |
May 01, 2008
| Webcast & Update May 8 |
April 22, 2008
| Phase 1a Update |
April 21, 2008
| Share Options Extended |
January 14, 2008
| RVX-208's Early Success in Phase 1a |
December 10, 2007
| Phase 1 Clinical Trial Starts for RVX-208 |
November 29, 2007
| RVX only Canadian company to win World Economic Forum award |
November 05, 2007
| Dr. Jacques Genest Presents RVX-208 Data at the American Heart Association Conference |
October 12, 2007
| RVX Presenting at IAS in Santorini, Greece |
October 04, 2007
| Resverlogix Presents Data at DALM Scientific Conference |
September 17, 2007
| Stella Thomson Joins RVX Board of Directors |
September 12, 2007
| RVX Data Published in Current Opinion in Investigational Drugs |
September 10, 2007
| TGF-Beta Shield Potential New Therapy for Glaucoma |
September 04, 2007
| Amended Finance - Interest Rate Reduction |
August 27, 2007
| Interest Rate Increase |
August 14, 2007
| RVX Wins Frost & Sullivan's Excellence in Technology Award |
August 13, 2007
| Interest Rate Increase |
July 31, 2007
| RVX To Host Live Teleconference |
July 25, 2007
| Additional Proof-of-Concept in Non-Human Primates |
July 20, 2007
| RVX to Present Data at DALM Conference |
July 12, 2007
| Dr. Roger Newton speaks of Resverlogix |
June 08, 2007
| US $25M Bought Deal Closed |
June 06, 2007
| RVX to Close US $25M Bought Deal on June 7, 2007 |
June 05, 2007
| Resverlogix Closes US $25M Bought Deal |
April 25, 2007
| 28 & 42 Day Monkey Data |
April 09, 2007
| Webcast/Teleconference Corporate Update |
April 02, 2007
| ApoA-I White Paper |
April 02, 2007
| ACC Meeting Highlights Need for ApoA-I |
March 26, 2007
| Clinical Advisory Board Endorses RVX-208 |
March 20, 2007
| IND & Microdosing Update |
March 07, 2007
| RVX-208 Passes Key Toxicology Milestone |
March 05, 2007
| Alzheimer's Research Commences |
January 30, 2007
| Drs. Radar and Genest Join RVX Clinical Review Committee |
January 25, 2007
| RVX Hires Advisor for Strategic Alternatives |
January 05, 2007
| RVX Secures 17M Financing |
January 02, 2007
| Convertible Debt Financing |
December 20, 2006
| Drs. Barter and Shah Join CRC |
December 05, 2006
| RVX208 is positioned as a leader in ApoA-I/HDL Marketplace |
November 29, 2006
| Lead compound RVX-208 Increases ApoA-I By 150% |
November 14, 2006
| Expert Panel Reviews ApoA-I Enhancing Technologies |
September 28, 2006
| Resverlogix Corp. First Lead RVX-208 Raises ApoA-I up to 180% |
September 11, 2006
| Resverlogix Corp. Annouces First Man Trial |
August 23, 2006
| Resverlogix Corp. Granted Foreign Private Issuer Status |
August 14, 2006
| Resverlogix Corp. Expands CVD Franchise |
August 11, 2006
| ResVerlogix Announces Normal Course Issuer Bid |
July 24, 2006
| Resverlogix Corp. Announces Live Webcast Update |
April 28, 2006
| Resverlogix Corp. NexVas™ Education Program Wins Prestigious International Telly Award |
April 25, 2006
| Resverlogix moves closer to IND with the addition of Dr. Gregory S. Wagner as Vice President Preclinical Development |
February 23, 2006
| Resverlogix Corp. ReVas™ Licensing Update |
February 22, 2006
| Resverlogix Announces Live Web Cast Update |
